205 related articles for article (PubMed ID: 19196964)
1. Anti-laminin gamma-1 pemphigoid.
Dainichi T; Kurono S; Ohyama B; Ishii N; Sanzen N; Hayashi M; Shimono C; Taniguchi Y; Koga H; Karashima T; Yasumoto S; Zillikens D; Sekiguchi K; Hashimoto T
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2800-5. PubMed ID: 19196964
[TBL] [Abstract][Full Text] [Related]
2. Pathogenicity of autoantibodies in anti-p200 pemphigoid.
Vafia K; Groth S; Beckmann T; Hirose M; Dworschak J; Recke A; Ludwig RJ; Hashimoto T; Zillikens D; Schmidt E
PLoS One; 2012; 7(7):e41769. PubMed ID: 22911854
[TBL] [Abstract][Full Text] [Related]
3. Anti-p200 pemphigoid.
Goletz S; Hashimoto T; Zillikens D; Schmidt E
J Am Acad Dermatol; 2014 Jul; 71(1):185-91. PubMed ID: 24767733
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of anti-laminin γ-1 pemphigoid by immunoblot analysis.
Solimani F; Pollmann R; Ishii N; Eming R; Hashimoto T; Schmidt T; Hertl M
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):735-741. PubMed ID: 29972879
[TBL] [Abstract][Full Text] [Related]
5. IgA anti-p200 pemphigoid.
Wozniak K; Hashimoto T; Fukuda S; Ohyama B; Ishii N; Koga H; Dainichi T; Kowalewski C
Arch Dermatol; 2011 Nov; 147(11):1306-10. PubMed ID: 22106117
[TBL] [Abstract][Full Text] [Related]
6. An attempt to develop mouse model for anti-laminin γ1 pemphigoid.
Koga H; Ishii N; Dainichi T; Tsuruta D; Hamada T; Ohata C; Karashima T; Furumura M; Hashimoto T
J Dermatol Sci; 2013 May; 70(2):108-15. PubMed ID: 23410740
[TBL] [Abstract][Full Text] [Related]
7. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.
Meijer JM; Diercks GF; Schmidt E; Pas HH; Jonkman MF
JAMA Dermatol; 2016 Aug; 152(8):897-904. PubMed ID: 27167149
[TBL] [Abstract][Full Text] [Related]
8. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid.
Groth S; Recke A; Vafia K; Ludwig RJ; Hashimoto T; Zillikens D; Schmidt E
Br J Dermatol; 2011 Jan; 164(1):76-82. PubMed ID: 20854435
[TBL] [Abstract][Full Text] [Related]
9. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid.
Dainichi T; Koga H; Tsuji T; Ishii N; Ohyama B; Ueda A; Natsuaki Y; Karashima T; Nakama T; Yasumoto S; Zillikens D; Hashimoto T
J Dermatol; 2010 Mar; 37(3):231-8. PubMed ID: 20507386
[TBL] [Abstract][Full Text] [Related]
10. A case of anti-laminin γ1 (p200) pemphigoid developed after dipeptidyl peptidase-4 inhibitor administration.
Nakatani K; Noborio R; Nomura Y; Ueki Y; Kiyohara T; Hashimoto T
J Dermatol; 2024 Jun; 51(6):869-872. PubMed ID: 38214494
[TBL] [Abstract][Full Text] [Related]
11. [Anti-p200 pemphigoid].
Holtsche MM; Goletz S; Zillikens D
Hautarzt; 2019 Apr; 70(4):271-276. PubMed ID: 30868255
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of immunofluorescence overlay antigen mapping in the identification of autoantigen in anti-p200 pemphigoid.
Kitayama S; Makino T; Hayashi M; Mizawa M; Ishii N; Hashimoto T; Shimizu T
J Dermatol; 2023 Sep; 50(9):1194-1198. PubMed ID: 37082790
[TBL] [Abstract][Full Text] [Related]
13. [Anti-p200 pemphigoid: a spectacular response to dapsone].
Munsch C; Prey S; Joly P; Meyer N; Lamant L; Livideanu C; Viraben R; Paul C
Ann Dermatol Venereol; 2011 Nov; 138(11):739-42. PubMed ID: 22078034
[TBL] [Abstract][Full Text] [Related]
14. Laminin β4 is a constituent of the cutaneous basement membrane zone and additional autoantigen of anti-p200 pemphigoid.
Goletz S; Pigors M; Lari TR; Hammers CM; Wang Y; Emtenani S; Aumailley M; Holtsche MM; Stang FH; Weyers I; König IR; Has C; Radzimski C; Komorowski L; Zillikens D; Schmidt E
J Am Acad Dermatol; 2024 Apr; 90(4):790-797. PubMed ID: 37992812
[TBL] [Abstract][Full Text] [Related]
15. [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].
Raffin D; Delaplace M; Roussel A; Estève E
Ann Dermatol Venereol; 2013 Dec; 140(12):784-7. PubMed ID: 24315224
[TBL] [Abstract][Full Text] [Related]
16. A long-term study of a patient with anti-p200 pemphigoid: correlation of autoantibody levels with disease activity and an example of epitope spreading.
Monshi B; Groth S; Richter L; Schmidt E; Zillikens D; Rappersberger K
Br J Dermatol; 2012 Nov; 167(5):1179-83. PubMed ID: 22639938
[TBL] [Abstract][Full Text] [Related]
17. Anti-p200 Pemphigoid: A Systematic Review.
Kridin K; Ahmed AR
Front Immunol; 2019; 10():2466. PubMed ID: 31695695
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo pathogenicity of anti-laminin γ1 autoantibodies.
Florea F; Bernards C; Caproni M; Kleindienst J; Hashimoto T; Koch M; Sitaru C
Am J Pathol; 2014 Feb; 184(2):494-506. PubMed ID: 24300951
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunological features and outcome of anti-p200 pemphigoid.
Commin MH; Schmidt E; Duvert-Lehembre S; Lasek A; Morice C; Estival JL; Debarbieux S; Rigal E; Pauwels C; De Quatrebarbes J; Roussel A; Goujon E; Stoebner PE; Jouen F; Joly P
Br J Dermatol; 2016 Oct; 175(4):776-81. PubMed ID: 27037896
[TBL] [Abstract][Full Text] [Related]
20. Subepidermal blistering disease with autoantibodies to both the p200 autoantigen and the alpha3 chain of laminin 5.
Shimanovich I; Petersen EE; Weyers W; Sitaru C; Zillikens D
J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S90-2. PubMed ID: 15858518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
